NASDAQ:RTRX

Travere Therapeutics - RTRX Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: $27.03
▼
$28.65
50-Day Range: $24.25
▼
$28.18
52-Week Range: $8.98
▼
$24.96

Volume: 454,289 shs
Average Volume: 412,277 shs
Market Capitalization: $1.46 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Travere Therapeutics (NASDAQ:RTRX) Stock

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Receive RTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RTRX Stock News Headlines

August 3, 2022 | tmcnet.com

Travere Therapeutics Provides Regulatory Updates on its Development Programs

July 26, 2022 | msn.com

Where Travere Therapeutics Stands With Analysts

May 17, 2022 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for Travere Therapeutics: Here's What You Need To Know

May 17, 2022 | finance.yahoo.com

Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

May 17, 2022 | markets.businessinsider.com

Analyst Ratings for Travere Therapeutics

May 9, 2022 | nasdaq.com

Travere Therapeutics Enters Oversold Territory (TVTX)

May 8, 2022 | seekingalpha.com

Travere Therapeutics' (TVTX) CEO Eric Dube on Q1 2022 Results - Earnings Call Transcript

March 5, 2021 | reuters.com

Travere Therapeutics Inc

December 1, 2020 | seekingalpha.com

Travere Therapeutics concludes enrollment in late-stage study of sparsentan in rare kidney disorder

November 17, 2020 | seekingalpha.com

Retrophin rebrands itself as Travere Therapeutics

November 16, 2020 | wsj.com

Retrophin, Founded by Martin Shkreli, Rebrands Itself as Travere Therapeutics - The Wall Street Journal

November 16, 2020 | finance.yahoo.com

Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.

November 12, 2020 | globenewswire.com

Retrophin Completes Acquisition of Orphan Technologies Nasdaq:RTRX - GlobeNewswire

November 12, 2020 | finance.yahoo.com

Retrophin Completes Acquisition of Orphan Technologies

November 9, 2020 | nasdaq.com

Regeneron Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year - Nasdaq

November 9, 2020 | finance.yahoo.com

Retrophin, Inc. (NASDAQ:RTRX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$33.33 - Yahoo Finance

November 9, 2020 | nasdaq.com

Retrophin, Inc. (NASDAQ:RTRX) Just Reported And Analysts Have Been Lifting Their Price Targets

November 9, 2020 | finance.yahoo.com

Retrophin, Inc. (NASDAQ:RTRX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$33.33

November 8, 2020 | seekingalpha.com

Retrophin's (RTRX) CEO Eric Dube on Q3 2020 Results - Earnings Call Transcript - Seeking Alpha

November 6, 2020 | seekingalpha.com

Retrophin EPS beats by $0.07, beats on revenue

November 6, 2020 | finance.yahoo.com

Retrophin: 3Q Earnings Snapshot - Yahoo Finance

November 5, 2020 | finance.yahoo.com

Retrophin (RTRX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance Australia

November 5, 2020 | globenewswire.com

Retrophin Reports Third Quarter 2020 Financial Results Nasdaq:RTRX - GlobeNewswire

November 5, 2020 | finance.yahoo.com

Retrophin Reports Third Quarter 2020 Financial Results

November 5, 2020 | finance.yahoo.com

Retrophin (RTRX) Reports Q3 Loss, Tops Revenue Estimates

See More Headlines

Receive RTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RTRX Company Calendar

Last Earnings: 11/05/2020
Today: 8/16/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RTRX
CUSIP: N/A
CIK: 1438533
Web: www.retrophin.com
Phone: (888) 969-7879
Fax: N/A
Employees: 221
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-146,430,000.00
Net Margins: -49.13%
Pretax Margin: N/A
Return on Equity: -36.38%
Return on Assets: -14.90%

Debt

Debt-to-Equity Ratio: 0.66
Current Ratio: 7.23
Quick Ratio: 7.14

Sales & Book Value

Annual Sales: $175.34 million
Price / Sales: 8.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.15 per share
Price / Book: 5.55

Miscellaneous

Outstanding Shares: 51,052,000
Free Float: N/A
Market Cap: $1.46 billion
Optionable: Optionable
Beta: 0.67

Key Executives

Eric Dube
President, Chief Executive Officer & Director
Laura M. Clague
Chief Financial & Accounting Officer
Bill Rote
Senior VP, Head-Research & Development
Noah L. Rosenberg
Chief Medical Officer
Elizabeth E. Reed
Secretary, Senior Vice President & General Counsel

Key Competitors

View All Competitors

RTRX Stock - Frequently Asked Questions

How were Travere Therapeutics' earnings last quarter?: Travere Therapeutics, Inc. (NASDAQ:RTRX) issued its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative trailing twelve-month return on equity of 36.38% and a negative net margin of 49.13%.
What other stocks do shareholders of Travere Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Travere Therapeutics investors own include CVS Health (CVS), Gilead Sciences (GILD), TG Therapeutics (TGTX), Dynavax Technologies (DVAX), Novavax (NVAX), Sangamo Therapeutics (SGMO), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), OPKO Health (OPK) and Exelixis (EXEL).

What is Travere Therapeutics' stock symbol?: Travere Therapeutics trades on the NASDAQ under the ticker symbol "RTRX."
What is Travere Therapeutics' stock price today?: One share of RTRX stock can currently be purchased for approximately $28.59.
How much money does Travere Therapeutics make?: Travere Therapeutics (NASDAQ:RTRX) has a market capitalization of $1.46 billion and generates $175.34 million in revenue each year. The biopharmaceutical company earns $-146,430,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.
How many employees does Travere Therapeutics have?: The company employs 221 workers across the globe.
How can I contact Travere Therapeutics?: Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.retrophin.com. The biopharmaceutical company can be reached via phone at (888) 969-7879 or via email at ir@retrophin.com.

This page (NASDAQ:RTRX) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms